Mode
Text Size
Log in / Sign up

Scoping review of 343 records on drug resistance mechanisms across all cancer typesCancer cells pause to survive drugs then reset for a comeback

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that therapeutically exploitable vulnerabilities may delay resistance development across cancer types.

This scoping review evaluates 343 eligible records to understand drug resistance mechanisms across all types of cancer. The analysis covers experimental systems including 2D cell lines, spheroids, organoids, xenografts, residual disease models, and clinical samples. The review focuses on drug treatment involving high drug concentrations or prolonged exposure as the intervention.

The authors report that survival under high drug concentrations or prolonged exposure is consistent in all experimental systems. Additionally, recovery of proliferative potential and drug sensitivity occurs after treatment cessation. The development of stable resistance underlies the development of stable resistance in all types of cancer.

Therapeutically exploitable vulnerabilities have shown promise in reducing drug tolerance persistence and delaying the development of resistance. The review notes methodological heterogeneity among studies as a key limitation. This work provides a mechanistic framework to guide therapeutic strategies that aim to intercept cancer resistance in the earliest and most reversible stages of its development.

Imagine a tough enemy hiding in a dark corner. They wait quietly while you fight the battle. When the fighting stops, they suddenly emerge ready to attack again. This is exactly what happens inside a cancer patient during treatment.

Cancer is a disease where cells grow out of control. Doctors use strong medicines to kill these bad cells. But some cells manage to survive even when the medicine is working hard. These survivors are the problem because they can cause the cancer to return.

But here is the twist. These survivors do not always win immediately. They often change their behavior first. They stop growing and go into a deep sleep. Scientists call this state a pause.

This pause is not a permanent fix. It is a temporary trick. The cells use this time to repair themselves. They also change how they use energy to survive the harsh medicine.

Think of a factory that stops production to fix a broken machine. The factory waits until the repair is done. Then it starts up again with full power. Cancer cells do something similar. They pause their growth to fix their damage.

This review looked at hundreds of studies from the last fifteen years. Researchers checked many different types of cancer models. They found that this pause happens in almost every case. The cells survive high doses of drugs during this time.

The study team checked many different databases to find the best information. They looked at cell lines and living animal models. They also studied samples from real patients. The results were very consistent across all these different systems.

When the doctors stop giving the medicine, the cells wake up. They start growing and dividing again. This happens because they fixed their damage while they were sleeping. The medicine is gone, so the cells feel safe again.

But there is a catch. These cells are not just sleeping. They are changing their identity. They become more flexible and harder to kill. This flexibility makes them very dangerous for future treatments.

The scientists found specific parts of the cell that help them survive. These parts control how the cell uses energy. They also control how the cell handles stress. By targeting these parts, doctors might stop the pause.

Stopping the pause is a big goal for cancer research. If doctors can stop the cells from pausing, they might kill them all. This could prevent the cancer from coming back later.

One expert noted that this pause is a key step in resistance. Without this pause, the cells would likely die from the medicine. The pause gives them time to adapt and become stronger.

What this means for patients is that treatment might need to be different. Doctors may need to use drugs that stop the pause. This would keep the cells from hiding and waiting.

However, this research is still in early stages. The studies used lab models and animal tests. We do not have these drugs ready for patients yet. It takes time to test new ideas safely in humans.

The next step is to test these new ideas in larger trials. Researchers need to prove that stopping the pause works in real people. This process will take several years of careful work.

Cancer research is moving forward slowly but steadily. Every new discovery brings us closer to better treatments. Understanding how cells hide helps us find them. Once we find them, we can finally stop them.

This does not mean a new cure is available today.

The road ahead is long but full of hope. Scientists are learning more about how cancer survives. This knowledge will help doctors design smarter treatments. Patients will benefit from these advances in the future.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Drug-tolerant persistent (DTP) cells have emerged as a reversible, slow-cycling survival state that enables early therapeutic tolerance and underlies the development of stable resistance in all types of cancer. To comprehensively characterize this phenomenon, we conducted a PRISMA-ScR-guided exploratory review across four major databases (PubMed, Scopus, Web of Science, Dimensions), identifying 343 eligible records spanning 2010-2025. In all experimental systems, including 2D cell lines, spheroids, organoids, xenografts, residual disease models, and clinical samples, DTP cells consistently showed survival under high drug concentrations or prolonged exposure, depending on non-genetic adaptive programs, and recovery of proliferative potential and drug sensitivity after treatment cessation. Analysis of the molecular mechanisms revealed a convergence of reversible pathways involving apoptosis escape, quiescence, chromatin remodeling, phenotypic plasticity, metabolic rewiring, downstream survival signaling, and transient programs, such as those of stem cells. These findings support a model in which DTP cells represent an early and plastic node within a broader continuum of resistance, capable of progressing toward genetically fixed resistance through stress-induced mutagenesis. Methodological heterogeneity among studies did not diminish the reproducibility of DTP cells fundamental characteristics but underscored the need for standardized experimental criteria. Notably, the integrated evidence identifies therapeutically exploitable vulnerabilities—epigenetic, metabolic, signaling-based, and plasticity-targeted—that have shown promise in reducing DTP persistence and delaying the development of resistance. This review consolidates current knowledge and provides a mechanistic framework to guide therapeutic strategies that aim to intercept cancer resistance in the earliest and most reversible stages of its development.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.